Similar articles for PMID: 2967353

Year	Number of Results
1986	3
1987	6
1988	9
1989	9
1990	9
1991	4
1992	8
1993	6
1994	4
1995	3
1996	2
1997	1
1999	1
2000	1
2003	2
2004	1
2006	3
2013	1
2014	1
2021	1
2023	0

1

Technetium-99m MAG3 kit formulation: preliminary results in normal volunteers and patients with renal failure.

Taylor A Jr, Eshima D, Christian PE, Wooten WW, Hansen L, McElvany K. Taylor A Jr, et al. J Nucl Med. 1988 May;29(5):616-22. J Nucl Med. 1988. PMID: 2967353 Free article.

2

Comparison of technetium-99m MAG3 kit with HPLC-purified technetium-99m MAG3 and OIH in rats.

Coveney JR, Robbins MS. Coveney JR, et al. J Nucl Med. 1987 Dec;28(12):1881-7. J Nucl Med. 1987. PMID: 2960790 Free article.

3

Clinical comparison of I-131 orthoiodohippurate and the kit formulation of Tc-99m mercaptoacetyltriglycine.

Taylor A Jr, Ziffer JA, Steves A, Eshima D, Delaney VB, Welchel JD. Taylor A Jr, et al. Radiology. 1989 Mar;170(3 Pt 1):721-5. doi: 10.1148/radiology.170.3.2521734. Radiology. 1989. PMID: 2521734

4

Technetium-99m labeled renal function and imaging agents: III. Synthesis of 99mTc-MAG3 and biodistribution of by-products.

Brandau W, Bubeck B, Eisenhut M, Taylor DM. Brandau W, et al. Int J Rad Appl Instrum A. 1988;39(2):121-9. doi: 10.1016/0883-2889(88)90157-8. Int J Rad Appl Instrum A. 1988. PMID: 2833469

5

Technetium-99m (99mTc) mercaptoacetyltriglycine: update on the new 99mTc renal tubular function agent.

Eshima D, Taylor A Jr. Eshima D, et al. Semin Nucl Med. 1992 Apr;22(2):61-73. doi: 10.1016/s0001-2998(05)80082-0. Semin Nucl Med. 1992. PMID: 1534184 Review.

6

Clinical evaluation of technetium-99m-L,L-ethylenedicysteine in patients with chronic renal failure.

Prvulovich EM, Bomanji JB, Waddington WA, Rudrasingham P, Verbruggen AM, Ell PJ. Prvulovich EM, et al. J Nucl Med. 1997 May;38(5):809-14. J Nucl Med. 1997. PMID: 9170451 Free article.

7

Kit preparation of technetium-99m-mercaptoacetyltriglycine: analysis, biodistribution and comparison with technetium-99m-DTPA in patients with impaired renal function.

Bannister KM, Penglis S, Bellen JC, Baker RJ, Chatterton BE. Bannister KM, et al. J Nucl Med. 1990 Sep;31(9):1568-73. J Nucl Med. 1990. PMID: 2144317 Free article.

8

Effects of altered physiologic states on clearance and biodistribution of technetium-99m MAG3, iodine-131 OIH, and iodine-125 iothalamate.

Taylor A Jr, Eshima D. Taylor A Jr, et al. J Nucl Med. 1988 May;29(5):669-75. J Nucl Med. 1988. PMID: 2967354

9

Estimation of technetium-99m-MAG3 plasma clearance in adults from one or two blood samples.

Russell CD, Taylor A, Eshima D. Russell CD, et al. J Nucl Med. 1989 Dec;30(12):1955-9. J Nucl Med. 1989. PMID: 2531219 Free article.

10

Evaluation of the hepatobiliary excretion of technetium-99m-MAG3 and reconstitution factors affecting radiochemical purity.

Shattuck LA, Eshima D, Taylor AT Jr, Anderson TL, Graham DL, Latino FA, Payne SE. Shattuck LA, et al. J Nucl Med. 1994 Feb;35(2):349-55. J Nucl Med. 1994. PMID: 8295009 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed